<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ju J</submitter><funding>NIEHS NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>533-42</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2860705</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(4)</volume><pubmed_abstract>The cancer-preventive activity of vitamin E has been studied. Whereas some epidemiological studies have suggested a protective effect of vitamin E against cancer formation, many large-scale intervention studies with alpha-tocopherol (usually large doses) have not demonstrated a cancer-preventive effect. Studies on alpha-tocopherol in animal models also have not demonstrated robust cancer prevention effects. One possible explanation for the lack of demonstrable cancer-preventive effects is that high doses of alpha-tocopherol decrease the blood and tissue levels of delta-tocopherols. It has been suggested that gamma-tocopherol, due to its strong anti-inflammatory and other activities, may be the more effective form of vitamin E in cancer prevention. Our recent results have demonstrated that a gamma-tocopherol-rich mixture of tocopherols inhibits colon, prostate, mammary and lung tumorigenesis in animal models, suggesting that this mixture may have a high potential for applications in the prevention of human cancer. In this review, we discuss biochemical properties of tocopherols, results of possible cancer-preventive effects in humans and animal models and possible mechanisms involved in the inhibition of carcinogenesis. Based on this information, we propose that a gamma-tocopherol-rich mixture of tocopherols is a very promising cancer-preventive agent and warrants extensive future research.</pubmed_abstract><journal>Carcinogenesis</journal><pubmed_title>Cancer-preventive activities of tocopherols and tocotrienols.</pubmed_title><pmcid>PMC2860705</pmcid><funding_grant_id>CA120915</funding_grant_id><funding_grant_id>R01 CA122474</funding_grant_id><funding_grant_id>CA122474</funding_grant_id><funding_grant_id>CA108455-05</funding_grant_id><funding_grant_id>R01 CA122474-04</funding_grant_id><funding_grant_id>CA133021</funding_grant_id><funding_grant_id>P30 ES005022</funding_grant_id><pubmed_authors>Yang CS</pubmed_authors><pubmed_authors>Yang Z</pubmed_authors><pubmed_authors>Ju J</pubmed_authors><pubmed_authors>Picinich SC</pubmed_authors><pubmed_authors>Kong AN</pubmed_authors><pubmed_authors>Suh N</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cancer-preventive activities of tocopherols and tocotrienols.</name><description>The cancer-preventive activity of vitamin E has been studied. Whereas some epidemiological studies have suggested a protective effect of vitamin E against cancer formation, many large-scale intervention studies with alpha-tocopherol (usually large doses) have not demonstrated a cancer-preventive effect. Studies on alpha-tocopherol in animal models also have not demonstrated robust cancer prevention effects. One possible explanation for the lack of demonstrable cancer-preventive effects is that high doses of alpha-tocopherol decrease the blood and tissue levels of delta-tocopherols. It has been suggested that gamma-tocopherol, due to its strong anti-inflammatory and other activities, may be the more effective form of vitamin E in cancer prevention. Our recent results have demonstrated that a gamma-tocopherol-rich mixture of tocopherols inhibits colon, prostate, mammary and lung tumorigenesis in animal models, suggesting that this mixture may have a high potential for applications in the prevention of human cancer. In this review, we discuss biochemical properties of tocopherols, results of possible cancer-preventive effects in humans and animal models and possible mechanisms involved in the inhibition of carcinogenesis. Based on this information, we propose that a gamma-tocopherol-rich mixture of tocopherols is a very promising cancer-preventive agent and warrants extensive future research.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Apr</publication><modification>2021-03-07T08:54:29Z</modification><creation>2019-03-27T00:30:23Z</creation></dates><accession>S-EPMC2860705</accession><cross_references><pubmed>19748925</pubmed><doi>10.1093/carcin/bgp205</doi></cross_references></HashMap>